Seock‐Ah Im

Research interests

Publications

• Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407086

• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.24.00920

• Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2404625

• Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2409932

• Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203690

• Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)02420-5

• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2202809

• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.09.159

• A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

  ESMO Open · 2022 · https://doi.org/10.1016/j.esmoop.2022.100639

• Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30754-3

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.019

• Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

  JAMA Oncology · 2021 · https://doi.org/10.1001/jamaoncol.2020.7932

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32531-9

• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30863-0

• Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911149

• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1810527

• Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.9909

• Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1809615

• Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30450-3

• Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30450-3

• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1706450

• Palbociclib and Letrozole in Advanced Breast Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1607303

• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00613-0

• Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1113216

Current projects

No projects listed.